Conventional Radioiodine Therapy for Differentiated Thyroid Cancer
This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients with differentiated thyroid cancer. Topics reviewed include definitions; staging; the 2 principal methods for selection of 131-I dosage; the indications for ablation, adjuvant treatment, and treatment; the recommendations for the use of 131-I contained in the guidelines of the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging; the dosage recommendations and selection of dosage approach for 131-I by these organizations; the use of recombinant human thyrotropin for radioiodine ablation, adjuvant therapy, or treatment; and the MedStar Washington Hospital Center approach.
Source: Endocrinology and Metabolism Clinics of North America - Category: Endocrinology Authors: Dorina Ylli, Douglas Van Nostrand, Leonard Wartofsky Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Hospitals | Iodine | Nuclear Medicine | Radioiodine Therapy | Thyroid | Thyroid Cancer